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Abstract: 
Purpose 
Arginine methylation (ArgMe) is one of the most ubiquitous post-translational modifications, and 
hundreds of proteins undergo ArgMe in e.g. brain. However, the scope of ArgMe in many tissues, 
including the heart, is currently under explored. Here, we aimed to 1) identify proteins undergoing 
ArgMe in human organs, and 2) expose the relevance of ArgMe in cardiac disease.  
This is the accepted version of the following article: Onwuli, D. O., Rigau-Roca, L., Cawthorne, C. and Beltran-Alvarez, P. 
(2017), Mapping arginine methylation in the human body and cardiac disease. Prot. Clin. Appl., 11: issue 1-2, 1600106, 
which has been published in final form at http://dx.doi.org/10.1002/prca.201600106
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Experimental design 
We used publicly available proteomic data to search for ArgMe in 13 human tissues. We used glucose 
to induce H9c2 cardiac-like cell hypertrophy. 
 
Results 
Our results show that ArgMe is mainly tissue-specific; nevertheless, we suggest an embryonic origin 
of core ArgMe events. In the heart, we found 103 mostly novel ArgMe sites in 58 non-histone 
proteins. We provide compelling evidence that cardiac protein ArgMe is relevant to cardiomyocyte 
ontology, and important for proper cardiac function. This is highlighted by the fact that genetic 
mutations affecting methylated arginine positions are often associated with cardiac disease, including 
hypertrophic cardiomyopathy. We provide pilot experimental data suggesting significant changes in 
ArgMe profiles of H9c2 cells upon induction of cell hypertrophy using glucose.  
Conclusions and clinical relevance 
Our work calls for in-depth investigation of ArgMe in normal and diseased tissues, using methods 
including clinical proteomics. 
 
Statement of Clinical Relevance 
Arginine methylation (ArgMe) is the subject of intense research in the context of cancer, which has 
included the development and testing of tens of ArgMe inhibitors in pre-clinical studies over the last 
decade. Here, we propose to further the research of ArgMe in the setting of cardiac disease. We 
provide evidence supporting the notion that ArgMe plays key roles in cardiac tissue morphogenesis 
and function. Our pilot data suggest that cardiac protein ArgMe profiles change significantly upon 
induction of cardiac-like cell hypertrophy using high glucose. Based on these results, we believe that 
researchers with an interest in cardiology and clinical proteomics could consider research in ArgMe as 
a new, and clinically relevant, research opportunity, given 1) the growing number of (bio)chemical 
and analytical tools to study ArgMe, 2) the increasing incidence of diabetic cardiomyopathy, and 3) 
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the need for new strategies for prevention, diagnosis, and treatment of cardiac hypertrophy, a disease 
with no current cure.  
 
 
1. Introduction 
Arginine methylation (ArgMe) is one of the ca. 200 known protein post-translational 
modifications (PTMs) [1], whereby one (monoArgMe) or two (diArgMe) methyl groups are 
transferred from S-adenosyl-L-methionine (SAM) to target arginine residues within proteins. ArgMe 
is catalysed by Protein Arginine Methyl Transferases (PRMTs), of which there are at least 9 distinct 
enzymes encoded in the human genome. These enzymes are named PRMT1-9, and are classified into 
three different types. While all PRMTs catalyse monoArgMe, Type I PRMTs including PRMT1, -3, -
4, -6, and -8, additionally lead to asymmetric diArgMe (ω-NG,NG- dimethylarginine), while Type II 
PRMTs such as PRMT5 and -9 symmetrically dimethylate target Arg residues leading to ω-NG,N’G- 
dimethylarginine. PRMT7 is a Type III PRMT and generates monoArgMe only. MonoArgMe, 
asymmetric and symmetric diArgMe differently increase the hydrophobicity and size of the residue, 
and change the geometry of hydrogen bonding [2].  
Recent studies have revealed 500-1000 ArgMe sites in HCT116 cells (a colon cancer cell 
line), primary T cells, and mouse brain [3, 4]. These figures make ArgMe one of the top 10 most 
ubiquitous PTMs [5], however, ArgMe has not been comprehensively investigated in many tissues. 
For instance, only a handful of non-histone proteins, including Desmoplakin, GATA4, NaV1.5 and 
PGC-1α, are known to undergo ArgMe in the heart [6-11].  
PRMTs have been described in animal cells, yeast, and plant cells [12], and homologs of the 
two major PRMTs (i.e. PRMT1 and -5) have been reported in many eukaryotes [13]. Many PRMTs 
are essential during animal embryogenesis; for example PRMT1 is critical for mouse embryo viability 
[14, 15], and zebrafish embryo development [16]. PRMT3 null mice show retarded growth during 
gestation [17], PRMT4 (also known as CARM1) null mice die perinatally [18], and loss of PRMT5 is 
embryonic lethal [19]. PRMT2, -6, -7, and -8 knockout mice are viable, although specific 
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abnormalities have been reported [20-23]. Despite these and other landmark studies, we are still 
lacking an understanding of the conservation of ArgMe along tissues that share common embryonic 
origin (e.g. that derive from a given germ layer). 
Recent high-resolution proteomic investigations by the group of Akhilesh Pandey have 
provided the proteomes of several human tissues, including that of the heart [24]. Importantly, the raw 
data as acquired by mass spectrometry are available in public data repositories. ArgMe is considered a 
stable PTM [2, 25], and therefore published proteomic data are amenable to further interrogation for 
ArgMe. To uncover the scope of ArgMe in the human body, we searched the data of Pandey (13 
human tissues) for ArgMe. To test whether ArgMe events are mostly organ-specific or, on the other 
hand, have a common embryonic origin, we compared proteins undergoing ArgMe in tissues derived 
from the 3 germ layers (endoderm, mesoderm and ectoderm). We further set ourselves to uncover the 
relevance of ArgMe in the physiology of the heart by analysing proteomic and genetic data as well as 
by using H9c2 cardiac-like cells as an experimental model of cardiac cell hypertrophy. 
 
2. Materials and methods 
2.1 Bioinformatics 
We downloaded raw data from the PRIDE database, Project PXD000561 by Pandey et al. [24]. For 
each tissue, all available files (typically 48-124 files, 500-1000 Mb each) were analysed using 
MaxQuant (v. 1.5.3.28) to quest the raw data for protein ArgMe. We set Arg/Lys mono- and 
dimethylation, as well as Met oxidation, and acetylation of protein N-terminus, as variable protein 
modifications. This enabled database searching for Arg residues taking into account that they may or 
may not be methylated. Cys carbamidomethylation was set as a fixed modification. Results were 
searched against SwissProt Human database (April, 2015). The rest of MaxQuant parameters was 
essentially as default. Allowed peptide length range was 8-25 amino acids. False discovery rate was 
set at 0.01, and minimum score for modified peptides was set at 40. Peptide mass tolerance was 4.5 
ppm for parent ion spectra and 20 ppm for MS/MS spectra. A maximum of two missed cleavages was 
allowed.  
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For the analysis of cardiac proteins undergoing ArgMe in fetal and adult heart, we worked 
with 117 raw files for adult heart, corresponding to the pooling of 15 adult, histologically normal, 
cardiac samples; and 104 files for fetal heart, corresponding to the pooling of 12 fetal, histologically 
normal, cardiac samples. MaxQuant analysis was done as before. 
 ArgMe sites in the different tissues were compared using online Venn diagrams makers 
(http://bioinformatics.psb.ugent.be/webtools/Venn/). Gene names and protein IDs were as in 
ENSEMBL/ UNIPROT. Gene Ontology (GO) term enrichment analysis was done using GOrilla [26, 
27], with two sets of data (target and background lists of proteins). Target proteins were proteins 
undergoing ArgMe in a tissue / group of tissues, and background was the proteome of the 
corresponding tissue (as identified by MaxQuant). 
 
2.2 H9c2 cells and induction of H9c2 cell hypertrophy 
H9c2 embryonic cardiac myoblast cells were purchased from ATCC UK (CRL-1446), and maintained 
in low glucose Dulbecco Modified Eagle’s Medium (Gibco, Gaithersburg, MD) supplemented with 
10% fetal bovine serum (Gibco) in a humidified incubator at 5% CO2 and 37 °C. For subculturing, 
cells were passaged every 2-3 days at 80% confluence. Induction of H9c2 hypertrophy using glucose 
was done following recently published protocols [28, 29]. Briefly, the day after seeding, H9c2 cell 
hypertrophy was induced by adding 30 mM glucose (final concentration, from 1 M sterile glucose 
stock) to the growth medium. Cultures were maintained for 72 h under these conditions, and then 
processed for cell size imaging and Western blot (see below). In parallel, H9c2 control cells were 
cultured without the addition of extra glucose. 
 
2.3 Measurement of H9c2 cell size 
Experiments were started by seeding 1 x 10
5
 H9c2 cells on cover slips in 6-well cell culture plates, 
and H9c2 cell hypertrophy was induced using glucose as above. After 72 hours treatment, cells were 
thoroughly washed, permeabilised using 1% Triton X-100, and incubated with 1% Rhodamine 
Phalloidin [#R415, ThermoFisher, Grand Island, NY] for 30 minutes at room temperature to visualise 
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F-actin by red/orange fluorescence. Slides were examined by fluorescence microscopy, and cell size 
was quantified using Image J [30]. Experiments were done in duplicate, values are reported as mean ± 
SD, and t-student test was used to assign statistical significance. 
 
2.4 Detection of H9c2 protein ArgMe using Western blot 
Experiments were started by seeding 1.6 x 10
6
 H9c2 cells in T75 cell culture flasks, and H9c2 cell 
hypertrophy was induced using glucose as above. After 72 hours treatment, cells were thoroughly 
washed in PBS, harvested, and pelleted. Cell pellets were lysed in 100 µl Laemmli buffer, and 
samples were briefly sonicated to reduce viscosity. Total protein lysates were then resolved on 10% 
acrylamide SDS-PAGE gels, and proteins transferred to nitrocellulose membranes (GE Healthcare 
Life Sciences, Buckinghamshire, UK) by Western blot. Membranes were probed using specific 
antibodies targeting mono- and diArgMe antibodies (#8015 and #13522, Cell Signalling Technology, 
Danvers, MA), as well as β-actin and GAPDH (both from Abcam, Cambridge, UK) as protein loading 
controls, and developed using ECL reagents (#WBLUF0100, Millipore, Hertfordshire, UK). 
Experiments were done in duplicate. 
 
3. Results 
 
3.1 Most ArgMe sites are tissue specific, although core ArgMe events seem to have an 
embryonic origin   
To define the “arginine methylome” of a number of human tissues, we interrogated the data 
previously published by the group of Pandey [24], for protein ArgMe in 13 human tissues (see flow 
chart in Figure 1A). We selected tissues derived from the 3 germ layers including colon, lung, 
pancreas, rectum, urinary bladder (endoderm), kidney, heart, ovary, prostate, testis (mesoderm), 
frontal cortex, retina, and spinal cord (ectoderm). Using MaxQuant, we generated a list of proteins 
undergoing mono- and diArgMe in each tissue (Supp. Tables 1 to 13). On average, 224 proteins (ca. 
337 sites) undergoing ArgMe were detected per tissue at a false discovery rate of 1%.  
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Approximately 53% and 58% mono- and diArgMe sites, respectively, were tissue specific. 
We defined “core” ArgMe events as those ArgMe sites conserved in at least 4 tissues in endoderm- or 
mesoderm-derived tissues, or throughout the 3 ectoderm-derived tissues. On average, core ArgMe 
events represented 7% and 13% of the total number of mono- and diArgMe sites per tissue, 
respectively (Table 1).  
We then compared core ArgMe events among germ layers. We identified 5 mono- and 3 
diArgMe sites conserved in all germ layers. We classified some ArgMe sites common to endoderm-
and-mesoderm, or mesoderm-and-ectoderm, but we did not find ArgMe sites common to endoderm-
and-ectoderm derived tissues (Figures 2A and 2B, and Table 2). To validate our results, we assessed 
the novelty of our 56 core ArgMe events, and found that 25 had previously been reported [31], (Table 
2). It should be mentioned at this point that during the manual curation step a range of potential 
contaminants, including hemoglobins, keratins and immunoglobulins, were found as undergoing core 
ArgMe, but excluded from our analyses. 
 
3.2 One hundred and three ArgMe sites in 58 non-histone proteins are conserved in fetal and 
adult heart 
Based on our results above, we hypothesized that ArgMe sites essential to tissue ontology must be 
conserved in fetal and adult tissues. We decided to test this hypothesis using the heart as a model 
system. First, we analysed protein expression and ArgMe in fetal (Supp. Table 14) compared to adult 
samples (Figure 1B, and Figures 2C and 2D). We found that 103 ArgMe sites in 58 non-histone 
proteins were conserved in fetal and adult heart (Supp. Table 15). Of note, 91 out of these 103 ArgMe 
sites were novel (Supp. Table 15), whereas 12 sites had previously been observed in other cells / 
tissues [31].  
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3.3 GO terms essential to cardiomyocytes are enriched in proteins undergoing ArgMe in the 
heart  
Next, we addressed the question of whether cardiac protein ArgMe is relevant to cardiomyocyte 
physiology. We searched for enrichment in GO terms in our subset of 62 methylated cardiac proteins 
(including 58 found here, as well as Desmoplakin, GATA4, NaV1.5 and PGC-1α). We used these 62 
methylated proteins as target set, and the 3124 proteins expressed in both fetal and adult heart as 
background set. We run the search using three ontologies, i.e. function, component and process. 
Importantly, GO terms related to cardiac muscle contraction, cardiomyocyte cytoskeleton and cardiac 
tissue morphogenesis were clearly enriched in methylated proteins (Supp. Table 16).  
 
3.4 Damaging mutations have been reported in many ArgMe sites of cardiac proteins 
We searched for human mutations at Arg positions found to be methylated in cardiac proteins. We 
queried the public version of the Human Gene Mutation Database [32], and the Exome Aggregation 
Consortium (ExAC) browser (Cambridge, MA, http://exac.broadinstitute.org), both last accessed 
April 2016. Titin was excluded from this analysis as many mutations in titin are currently of unknown 
significance [33]. In more than half of the cases (64 out of 109 methylation sites), we found mutations 
precisely at the would-have-been-methylated Arg residues. All mutations were rare (allele frequency 
< 0.001, as available in the ExAC browser). The vast majority of the mutations (50 out of 64) were 
either known to be associated with cardiac disease, or predicted to be damaging by PolyPhen-2 [34], 
(Supp. Table 15), hinting at the importance of an Arg at those positions. 
It should be noted that we sometimes found more than one reported mutation at the same 
residue, e.g. R31H, R31C and R31G in MYL3 (Uniprot P08590). Estimation of pathogenicity by 
Polyphen-2 gave in some cases different predictions, i.e. probably damaging for R31H and R31C, 
while benign for R31G. Our conservative interpretation of these cases was that the Arg was not 
essential at that particular position, and we only considered the benign mutation, when building Supp. 
Table 15.  
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3.5 ArgMe co-localises with other PTMs in many cardiac proteins 
In an attempt to identify a general mechanism of action of ArgMe in cardiac tissue, we searched our 
dataset of cardiac proteins undergoing ArgMe for co-occurrence of ArgMe and other PTMs. We 
searched PTMs databases (Uniprot, Phosphositeplus, [31]) for the presence of PTMs on residues 
neighbouring ArgMe sites. We found a total of 63 PTMs in residues that resided within ± 5 positions 
of 41 out of the 109 ArgMe sites considered (103 new plus 11 previously known and excluding the 5 
ArgMe sites in titin). These PTMs included phosphorylation (Ser, Thr, or Tyr), Lys modifications 
(ubiquitination, acetylation, methylation), and ArgMe (Supp. Table 15).  
 
3.6 Preliminary observations suggest significant changes in protein ArgMe in a cell model of 
hypertrophic cardiomyopathy  
We noted that many of the genetic mutations associated with disease in Supp. Table 15 had been 
linked to hypertrophic cardiomyopathy. To provide experimental proof-of-concept that ArgMe can be 
relevant to cardiac disease, we used a recently established model of cardiac-like cell hypertrophy [28, 
29]. We treated H9c2 cells with glucose (30 mM for 72 h), and analysed cell size and global ArgMe 
patterns. We observed an increase in H9c2 cell size by 37% (Figure 3A and Supp. Figure 1), with 
concomitant slight, and general, reduction in protein mono- and diArgMe in glucose-treated H9c2 
cells (Figure 3B). We also noticed that the intensity of several protein bands significantly decreased, 
or bands were absent, after glucose treatment (filled arrows, Figure 3B), which was particularly 
obvious when visualising protein monoArgMe. In contrast, a protein band at ca. 31 KDa seemed to 
increase after glucose treatment (dotted arrow, Figure 3B). 
 
4. Discussion  
 
In this work we have identified proteins undergoing ArgMe in 13 human organs, based on published 
proteomic data. We propose that ArgMe events are mainly defined at the tissue level, although some 
ArgMe seems to derive from early embryonic events. In the heart, we found 58 proteins that are 
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methylated at 103 sites in both fetal and adult samples. Analysis of these data and our experiments 
using a cardiac-like cell model of hypertrophy suggest that ArgMe can play important roles in 
cardiomyocyte physiology.  
From a proteomic point of view, the scope of ArgMe in tissues has only recently begun to be 
explored. The availability of specific antibodies has revolutionised the search for global ArgMe marks 
beyond the histone code [3, 4, 35]; however, these experiments are very demanding in resources and 
time. Here, we generated a map of protein ArgMe in the human body by data mining. To our 
knowledge, the most relevant study to quality control our data is that from Guo et al [3], which 
described the arginine methylome of the mouse brain. In this work, researchers identified a total of 
807 monoArgMe sites (453 proteins) and 697 diArgMe sites (321 proteins). This compares with our 
list of 232 monoArgMe sites (177 proteins) and 139 diArgMe sites (109 proteins) in the human brain, 
including 60 proteins also identified by Guo et al. On the one hand, these numbers suggest that we 
could be underestimating the total number of ArgMe sites in our analyses. This could indeed be the 
case as our approach is clearly biased towards abundant proteins, while Guo et al enriched their 
samples in arginine methylated peptides [3]. On the other hand, Guo et al used a rather high precursor 
mass tolerance of 50 ppm for peptide identification using an Orbitrap Elite or a Q-Exactive mass 
spectrometer, which could lead to high false positive discovery rates, while we used 4.5 ppm. Also, it 
is conceivable that some ArgMe sites are species-specific (e.g. R680 in human NaV1.5 is replaced by 
H680 in mouse NaV1.5). Finally, our approach depends on the quality of primary proteomic data, for 
example on the total number of proteins identified. For instance, we identified ca. 4900 proteins in the 
brain, compared to 7000-8000 in e.g. pancreas, prostate, retina, and testis. While acknowledging these 
limitations, our data provide for the first time a framework to picture ArgMe in the human body.  
In the original publication by the group of Pandey [24], Desmoplakin was identified by 81 
unique peptides in the adult heart, however, no Desmoplakin methylated peptides were detected in our 
analysis. Moreover, GATA4, NaV1.5 and PGC-1α were not identified in the original work [24], 
probably reflecting low protein abundance. Despite these limitations, our results increase the number 
of proteins thought to be methylated in the human heart from 4 (Desmoplakin, GATA4, NaV1.5, and 
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PGC-1α) to 62. PRMT1, -3, -4, and -5 are the most abundant methyltransferases in fetal and adult 
heart [24], and must be responsible for most of this ArgMe activity. This is consistent with previous 
work identifying the PRMTs that methylate Desmoplakin, GATA4, NaV1.5 and PGC-1α [6, 7, 9, 11]. 
Bulk ArgMe activity must be defined mainly at the level of the organ, as most (53-58%) 
ArgMe events were tissue-specific, although this could also reflect tissue-specific protein expression 
in some cases. We observed that 7-13% ArgMe sites were conserved in most tissues within a 
particular germ layer. As expected, many proteins undergoing these core ArgMe events (Table 2) 
were involved in RNA binding and processing [25], and we also noted the presence of proteins (and 
enrichment in GO terms) related to glycolysis. We propose that core ArgMe events are programmed 
from early embryonic stages, and that the lack of ArgMe at these sites / proteins could be responsible 
for some of the serious consequences of PRMT deletion as observed in animal models [14-19]. In 
support of this, loss of hnRNPs and PABPC1 ArgMe is likely to contribute to embryonic death of 
PRMT1 [15, 36], and PRMT4 [18] null mice, respectively, and indeed we found that hnRNPs and 
PABPC1 undergo several core ArgMe events in normal human tissues (Table 2).  
Bearing the above in mind, we hypothesised that ArgMe sites conserved along fetal and adult 
tissues must be particularly relevant to tissue function. Using the heart as a model to test this 
hypothesis, we found that proteins undergoing ArgMe in both fetal and adult cardiac tissue were 
specifically rich in GO terms essential to cardiomyocyte identity, relative to the common cardiac 
proteome. This supported a fundamental role of ArgMe in cardiomyocyte physiology, as proteins 
participating in critical cardiomyocyte functions (including contraction) and structures (e.g. Z-disk) 
seemed to be more likely to undergo ArgMe. In support of this, we found many disease-associated 
mutations affecting an Arg position shown to be methylated in both fetal and adult cardiac samples. It 
is tempting to speculate that, at least in some cases, the pathogenicity of the mutation may be due to 
the lack of protein regulation at that position by ArgMe. 
Building up from the observations that a) several proteins undergoing core ArgMe events 
were related to glucose metabolism (Table 2), and b) many of the mutations at ArgMe sites were 
associated with hypertrophic cardiomyopathy (Supp. Table 15), we decided to use a model of cardiac 
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cell hypertrophy induced by high glucose to experimentally link ArgMe to cardiac disease. H9c2 cells 
show similar hypertrophic responses to primary neonatal cardiomyocytes [37], and are the most 
widely used in vitro model of cardiomyocyte hypertrophy [38]. In our hands, treatment of H9c2 cells 
with 30 mM glucose for 3 days led to 37% increase in size, which is consistent with previous reports 
[28, 29]. We observed a general, subtle, decrease in ArgMe in glucose-treated H9c2 cells, which we 
rationalise by a decrease in PRMT and SAM cellular concentrations caused by the rapid cell growth, 
and leading to parallel reduction in ArgMe activity. In combination with this, the fact that protein 
synthesis is enhanced in hypertrophic cells [39] could lead to an apparent “dilution” of previous 
ArgMe at the total protein level. 
On the other hand, we observed specific events as the intensity of several protein bands was 
remarkably different upon glucose-induced cell hypertrophy. Although the identity of these proteins is 
currently unknown, our results suggest that specific changes in protein ArgMe occur following 
induction of cardiac-like cell hypertrophy using glucose. However, given the associations of PRMTs 
with cellular metabolism (both as regulating and regulated enzymes, [2]) it may be that other 
pathways contribute to the observed differences in ArgMe, and clearly many more studies are needed 
to establish a causal relationship between hypertrophy and abnormal ArgMe, or viceversa. In this 
respect, it has recently been shown that knockdown of PRMT5 leads to cardiomyocyte hypertrophy 
(through mechanisms that include GATA4 ArgMe-Lys acetylation interplay) [7]. Taking together our 
analysis of genetic mutations at ArgMe sites, and our pilot H9c2 experiments, we propose that 
abnormal ArgMe of specific proteins could be both cause and consequence of cardiac cell 
hypertrophy.  
ArgMe alters the hydrophobicity, size and bonding of Arg residues. These changes can affect 
protein-protein interactions and, for instance, recognition of proteins by enzymes catalysing other 
PTMs. For example, NaV1.5 R513 methylation and S516 phosphorylation regulate each other, with 
possible implications in cardiac disease [40]. Likewise, PGC-1α ArgMe / acetylation equilibrium is 
believed to play a role in cardiomyopathy associated to metabolic disorders [41]. Additionally, 
GATA4 ArgMe inhibits its acetylation [7]; while loss of ArgMe at R2834 reduces Desmoplakin 
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phosphorylation at S2839 [6]. Based on our findings and the above discussion, we propose that 
ArgMe cross-talks with other PTMs in at least 1/3 of the cases. However, ArgMe seems to be a stand-
alone protein in 2/3 of the methylation sites. This is perhaps not surprising, as ArgMe is a stable PTM 
[2, 25], which reduces the degrees of freedom for PTM interplays. We predict that systems 
approaches to ArgMe-PTMs cross-talk will increasingly incorporate engineered PRMTs and SAM 
analogues for target identification [42], followed by the study of the effect of ArgMe on an individual 
protein basis.  
 
Concluding Remarks 
In this work we have a) mapped ArgMe in 13 human tissues and proposed that most ArgMe activity is 
controlled at the organ level, while core ArgMe events are programmed from early embryonic stages; 
b) shown that there is a high frequency of cardiac disease-associated mutations at ArgMe sites 
conserved in fetal and adult heart, and that GO terms essential to cardiomyocyte ontology are 
enriched in these proteins; and c) provided experimental evidence that specific proteins undergo 
significant changes in ArgMe upon induction of cardiac-like cell hypertrophy. 
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Supplementary Tables 1-13. For each tissue, in alphabetical order, an excel file shows in different 
sheets total proteins identified, monoArgMe sites and diArgMe sites as retrieved from MaxQuant 
analyses. 
 
Supplementary Table 14. For fetal heart, an excel file shows in different sheets total proteins 
identified, monoArgMe sites and diArgMe sites as retrieved from MaxQuant analyses. 
 
Supplementary Table 15. List of non-histone proteins and ArgMe sites conserved in both fetal and 
in adult heart, mutations at ArgMe sites, and co-occurrence of other PTMs. Uniprot codes and gene 
names are shown, sorted by Uniprot code. Desmoplakin (P15924, DSP), GATA4 (P43694), NaV1.5 
(Q14524, SCN5A) and PGC-1α (Q9UBK2, PPARGC1A) are included. The star (*) symbol by the 
Uniprot code represents that the methylation site(s) has previously been reported in either the Uniprot 
or the Phosphositeplus Database [31]. PTMs are shown as follows: S-p, T-p or Y-p = phosphorylated 
Ser, Thr or Tyr; K-ac = acetylated Lys; K-m1 or m2 = mono- or dimethylated Lys; K-ub = 
ubiquitinated Lys; R-m1 or m2 = mono- or dimethylated Arg. 
 
Supplementary Table 16. GO term enrichment analysis of proteins in Supplementary Table 15. 
Biological Process, Molecular Function, and Component ontologies are shown in separate sheets.  
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Supplementary Figure 1. A. Images of control H9c2 cells used to quantify cell surface. B. Images of 
glucose-treated H9c2 cells used to quantify cell surface.  
 
 
Legends 
 
Figure 1. A. Flow chart illustrating our protocol to identify ArgMe sites in proteins from 13 human 
tissues. “Core” ArgMe sites were defined as those common to at least 4 tissues in endoderm- or 
mesoderm-derived tissues, or conserved throughout the 3 ectoderm-derived tissues. B. Flow chart 
illustrating our protocol to identify ArgMe sites conserved in fetal and adult heart. 
 
Figure 1 
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Figure 2. A. Venn-diagram comparing core monoArgMe sites conserved in tissues derived from the 3 
germ layers. B. Venn-diagram comparing core diArgMe sites conserved in tissues derived from the 3 
germ layers C. Venn-diagram comparing the total number of proteins identified as expressed in adult 
and fetal heart. D. Identification of 58 proteins undergoing ArgMe in adult and fetal heart (shaded 
intersection). 103 methylation sites in these 58 proteins were conserved in adult and fetal samples. 
 
Figure 2 
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Figure 3. A. Chart showing significant (P < 0.05) increase in cell size upon induction of H9c2 
hypertrophy by glucose. Control: 2740 ± 202 μm2 (n = 94 cells), Glucose-treated: 3743 ± 102 μm2 (n 
= 100 cells), B. ArgMe profiles of H9c2 cells (Control lane) and upon glucose-induced hypertrophy 
(Glucose lane). The membrane was sequentially blotted with antibodies targeting mono- and 
diArgMe, as well as actin and GAPDH as protein loading controls. Specific proteins (filled arrows) 
underwent remarkable reduction in ArgMe, and a protein at 31 KDa (dotted arrow) showed increased 
monoArgMe, after glucose treatment. 
 
Figure 3 
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Table 1. Number of mono- and diArgMe sites in tissues classified as per germ layer origin. For each 
tissue, the total number of mono and diArgMe sites is shown. The number of core ArgMe sites as well 
as the % this represents of the total number of mono- or diArgMe sites for that tissue are shown 
between brackets. 
Table 1 
Germ 
layer 
origin 
Tissue No. Mono-
ArgMe sites 
(No., % of 
core sites 
within germ 
layer) 
No. Di-ArgMe 
sites (No.,  
% of core 
sites within 
germ layer) 
Endo Colon 151 (10, 7%) 129 (19, 12%) 
Lung 103 (10, 10%) 75 (19, 21%) 
Pancreas 153 (10, 7%) 173 (19, 9%) 
Rectum 157 (10, 6%) 126 (19, 12%) 
Ur. bladder 195 (10, 5%) 144 (19, 11%) 
Meso Kidney 279 (18, 6%) 74 (21, 22%) 
Heart 221 (18, 8%) 61 (21, 26%) 
Ovary 297 (18, 6%) 286 (21, 6%) 
Prostate 279 (18, 6%) 128 (21, 12%) 
Testis 205 (18, 9%) 146 (21, 11%) 
Ecto Fr. cortex 234 (20, 8%) 140 (13, 7%) 
Retina 462 (20, 4%) 166 (13, 6%) 
Spinal cord 232 (20, 9%) 54 (13, 19%) 
 Average 228 (15, 7%) 131 (15, 13%) 
 
 
 
 
Table 2. Proteins undergoing core ArgMe sites in each germ layer, or combination of them, sorted 
alphabetically by gene name for each section. Type of ArgMe refers to monoArgMe (m1) or diArgMe 
(m2). Novelty of the ArgMe was assessed using Phosphositeplus as a reference [31].  
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Table 2 
Germ 
layer 
ENSEMBL ID Gene  
Name 
Gene Description ArgMe site, 
type  
Novel 
Endo 
+ 
Meso 
+ 
Ecto 
ENSP00000421592 ALYREF Aly/REF export factor  38, m2 No 
ENSP00000295006 CAPN2 Calpain 2, (m/II) large subunit 23, m1 Yes 
ENSP00000339063 EEF1A1 Eukaryotic translation elongation factor 1 α1 166, m1, m2 No 
ENSP00000408907 HSPA1A Heat shock protein family A (Hsp70) 1A 469, m1 No 
ENSP00000377440 RAB5C RAB5C, member RAS oncogene family 4, m1 Yes 
Endo 
+ 
Meso 
ENSP00000409681 C11orf68 UPF0696 protein c11orf68 14, m2 Yes 
ENSP00000359717 FHL1 Four and a half LIM domains 1 5, m2 Yes 
ENSP00000369594 FUS FUS RNA binding protein 215, 217, 
m2 
No 
ENSP00000354021 HNRNPA2 
B1 
Heterogeneous nuclear ribonucleoprotein 
A2/B1 
213, m1 No 
ENSP00000380446 PABPN1 Poly(A) binding protein, nuclear 1  17, m1, m2 No 
ENSP00000376899 PTGFRN Prostaglandin F2 receptor inhibitor 280, m1 Yes 
ENSP00000365950 RBM3 RNA binding motif (RNP1, RRM) protein 3 105, m2 No 
ENSP00000349748 SFPQ Splicing factor proline/glutamine-rich 19, 25, m2 No 
ENSP00000417952  TFG TRK-fused gene protein 385, m2 Yes 
Meso 
+ 
Ecto 
ENSP00000455917 ALDOA Aldolase, fructose-bisphosphate A 56, m1 Yes 
ENSP00000380070 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 248, m1 Yes 
ENSP00000283179 HNRNPU Heterogeneous nuclear ribonucleoprotein U 733, 739, 
m2 
No 
ENSP00000313007 PABPC1 Poly(A) binding protein 1 493, m2 No 
ENSP00000398599 YWHAZ 14-3-3 protein, zeta 41, m1 Yes 
Endo ENSP00000331699 EWSR1 EWS RNA binding protein 1 563, m2 No 
ENSP00000301785 HNRNPUL
2 
Heterogeneous nuclear ribonucleoprotein U-
like 2  
656, 684, 
m2 
No 
ENSP00000349748 SFPQ Splicing factor proline/glutamine-rich 693, m1 No 
ENSP00000435614 SLC22A25 Solute carrier family 22 member 25 84, m2 Yes 
ENSP00000484236 SLC38A5  Solute carrier family 38, member 5 349, m2 Yes 
ENSP00000400591 SNRPE Small nuclear ribonucleoprotein protein E 4, m2 Yes 
ENSP00000432282 TAGLN Transgelin 183, m1 No 
ENSP00000465435 ZMYND15  Zinc finger, MYND-type containing 15 145, m2 Yes 
Meso ENSP00000451979 APEX1 APEX nuclease  156, m1 Yes 
ENSP00000455329 CRIP1 Cysteine-rich protein 1 68, m1 No 
ENSP00000484789 HIST1H4E Histone cluster 1, h4e 55, m1 No 
ENSP00000354021 HNRNPA2 
B1 
Heterogeneous nuclear ribonucleoprotein 
A2/B1 
213, m2 No 
ENSP00000313327 HNRNPD Heterogeneous nuclear ribonucleoprotein D 296, m2 Yes 
ENSP00000215909 LGALS1 Lectin, galactoside-binding, soluble, 1 19, m1 Yes 
ENSP00000465404 PARK7 Parkinson protein 7 48, m1 Yes 
ENSP00000270142 SOD1 Superoxide dismutase 1 70, 116, m1 Yes 
ENSP00000258962 SRSF1 Serine/arginine-rich splicing factor 1 97, m1; 109, 
m1, m2 
No 
Ecto ENSP00000216254 ACO2 Aconitase 2 84, m1 Yes 
ENSP00000378731 ALDOA Aldolase, fructose-bisphosphate A 134, m1 Yes 
ENSP00000418795 CFAP44 Cilia- and flagella-associated protein 44 374, m1 Yes 
ENSP00000309539 DPYSL2 Dihydropyrimidinase like 2  227, 238, 
m1 
Yes 
ENSP00000258198 DYNC1LI2 Dynein, cytoplasmic 1, light chain 2 397, m1 No 
ENSP00000379069 G3BP2 Gtpase activating protein (SH3 domain) 
binding protein 2  
468, m2 No 
ENSP00000253408 GFAP Glial fibrillary acidic protein 300, m1 Yes 
ENSP00000353552 HNRNPK Heterogeneous nuclear ribonucleoprotein K 299, 303, 
m2 
No 
ENSP00000281938 HSPB8  Heat shock protein family B member 8 78, m2 No 
ENSP00000420813 PCMT1 Protein-L-isoaspartate O-methyltransferase 182, m1 Yes 
ENSP00000362413 PGK1 Phosphoglycerate kinase 1 206, m1 Yes 
ENSP00000371388 SRXN1 Sulfiredoxin 1 16, m2 No 
ENSP00000379933 TPI1 Triosephosphate isomerase 1 53, m1 Yes 
ENSP00000336799 TUBA1B Tubulin alpha 1b 221, m1 Yes 
ENSP00000446007 VIM Vimentin  304, m1 Yes 
ENSP00000462595 WSB1 WD repeat and SOCS box-containing 1 7, m2 Yes 
ENSP00000487356 YWHAE 14-3-3 protein, epsilon 4, m1 Yes 
 
 
